Exosomes, a Rapidly Emerging Therapeutic Platform

 

Exosomes are small, membrane-bound vesicles released by cells that play a crucial role in cell-to-cell communication by transferring proteins, lipids, and nucleic acids such as RNA and microRNA. Their unique biological properties—including targeted delivery, low toxicity, and the ability to modulate immune responses—make them promising candidates for treating a wide range of diseases.

Extracellular vesicles (EVs) and exosomes have emerged as pivotal players in various biological processes, ranging from cancer progression to neurodegenerative diseases, gene therapy, and even aging. EVs are lipid bilayer-delimited particles released by nearly all cell types into the extracellular space.

Exosomes are a specific subtype of EVs, defined by their biogenesis pathway—they originate from the endosomal system and are released upon fusion with the plasma membrane. EVs and exosomes carry a diverse cargo of proteins, lipids, and nucleic acids, facilitating intercellular communication and influencing numerous physiological and pathological conditions.

In disease treatment, exosomes can be used as natural or engineered vehicles to deliver therapeutic agents directly to target cells, particularly in cancer, where they may carry drugs or genetic material to tumor sites. They also show significant potential in regenerative medicine, supporting tissue repair and regeneration in conditions like heart disease, liver disease, and neurological disorders. Additionally, exosomes modulate the immune system, reducing inflammation and promoting anti-inflammatory effects, which is beneficial in autoimmune and inflammatory diseases such as psoriasis, atopic dermatitis, rheumatoid arthritis, and multiple sclerosis.

The versatility of exosomes extends to their use as biomarkers for disease diagnosis and monitoring, as well as in gene therapy for genetic disorders. At present, the primary challenge with exosome-based therapies lies in the lack of standardized, scalable, and reliable methods for isolating, purifying, and characterizing exosomes. Although exosome-based therapies are still largely experimental, ongoing research is rapidly expanding their clinical applications and understanding of their mechanisms.

EXOSOMES, TURNING DISEASE ENHANCERS INTO THERAPEUTICS

CANCER

Exosomes in Cancer Progression

Exosomes play a crucial role in cancer progression by modulating the tumor microenvironment. They facilitate communication between tumor cells and surrounding stromal cells, promoting tumor growth, angiogenesis, and metastasis. Tumor-derived exosomes (TEXs) can carry oncogenic proteins, RNAs, and other molecules that enhance the invasive and migratory capabilities of cancer cells. Moreover, exosomes can suppress immune responses, aiding in immune evasion by tumors. Exosomes also contribute to chemoresistance by transferring drug resistance traits between cancer cells.

Exosomes for Cancer Therapy

Exosomes show significant promise for cancer treatment due to their unique biological properties and versatility in therapeutic applications. These small extracellular vesicles can be engineered to deliver drugs, small interfering RNAs (siRNAs), or proteins directly to tumor cells, enhancing drug efficacy while reducing systemic toxicity. Exosomes deliver drugs to tumor cells primarily through a combination of surface-mediated targeting and cellular internalization mechanisms.

For example studies have shown loading exosomes with chemotherapeutic agents such as paclitaxel exhibit up to 50 times more cytotoxicity against drug-resistant cancer cells in vitro compared to free paclitaxel. Exosomes can also be used as vehicles for immunotherapy, carrying tumor antigens that stimulate the immune system to recognize and attack cancer cells, as demonstrated in preclinical studies for melanoma, glioma, and other cancers.

NEURODEGENERATIVE DISEASES

Exosomes in Neuro-Pathogenesis
In neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s, EVs and exosomes are involved in the spread of pathogenic proteins and the modulation of neuroinflammatory responses. They carry misfolded proteins like amyloid-beta, tau, and alpha-synuclein, contributing to disease progression.

Exosomes for Treating Neurodegenerative Disorders
Exosomes are being investigated as therapeutic agents for neurodegenerative diseases. They can transport proteins, nucleic acids (like microRNAs), and other molecules that can influence cellular function, reduce inflammation, promote neurogenesis, and support tissue repair, offering a novel approach to treating these debilitating conditions.

Their unique ability to cross the blood-brain barrier makes them particularly promising for treating neurological diseases such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, stroke, and traumatic brain injury.  For example exosomes have been engineered to deliver small interfering RNA (siRNA) targeting pathological proteins and provided neuroprotection. Exosomes are emerging as a transformative approach for neuro-restoration and cognitive improvement in neurological disorders.

EXOSOMES FOR THE TREATMENT OF OTHER HUMAN DISEASES

Cardiovascular Diseases
Recent research has demonstrated exosomes can be used to reduce cell death, improve cardiac function, decrease fibrosis, and promote angiogenesis after myocardial injury.

Autoimmune Disorders
Exosomes can modulate immune responses and have shown efficacy in experimental models of autoimmune diseases like rheumatoid arthritis and multiple sclerosis. They can deliver anti-inflammatory molecules, regulate T-cell populations, and restore immune balance more effectively than some conventional drugs. For example, glucocorticoid-loaded exosomes have outperformed standard therapies in animal models of autoimmune encephalomyelitis.

Infectious Diseases
While the provided sources focus more on cancer, regenerative medicine, and autoimmune diseases, exosomes are also being explored for infectious disease applications. Their natural role in intercellular communication and ability to carry bioactive molecules make them potential vehicles for delivering antiviral agents or modulating immune responses. Ongoing research is investigating how exosome-based therapies could enhance immune defense or directly target pathogens.

EXOSOMES FOR GENE THERAPY AND NUCLEIC ACID DELIVERY

Exosomes have shown promise as delivery vehicles for gene therapy as they can be loaded with various nucleic acids, including DNA, mRNA, miRNA, and siRNA, to modulate gene expression in target cells. Once delivered, exosomes efficiently enter recipient cells through various mechanisms, including endocytosis and membrane fusion, releasing their genetic cargo into the cytoplasm where it can exert therapeutic effects.

Their natural targeting capability can be further enhanced by genetic engineering, reducing off-target effects and toxicity compared to synthetic delivery systems. Exosome-based gene delivery is being explored for treating cancer, neurodegenerative disorders, and genetic diseases, with ongoing research to optimize loading efficiency, targeting, and scalability for clinical use.

CONCLUSION

In summary, exosomes are rapidly emerging as a transformative therapeutic platform with broad applicability across a spectrum of disease areas. Their unique capacity to deliver drugs, nucleic acids, and bioactive molecules with high specificity and minimal toxicity positions them as highly promising vehicles for targeted therapy.

Perhaps the highest therapeutic potential is where current treatments have low impact on disease progression, including cancer and neurodegenerative diseases. For cancer therapy, engineered exosomes enable precise tumor targeting, enhancing drug efficacy while mitigating side effects and overcoming challenges such as drug resistance and metastasis.  For neurodegenerative disorders, exosomes can cross the blood-brain barrier and deliver neuroprotective agents that may slow the progression of diseases like Alzheimer’s and Parkinson’s.

Other diseases where exosomes have therapeutic potential are cardiovascular, autoimmune and infectious disease.  Collectively, these advances underscore the immense therapeutic potential of exosomes and highlight their growing significance in modern medicine.

REFERENCES

Paskeh, M.D.A., Entezari, M., Mirzaei, S. et al. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. J Hematol Oncol 15, 83 (2022).

Recent advances in exosome-mediated nucleic acid delivery for cancer therapy. Journal of Nanobiotechnology 20, 279 (2022).

Whiteside, T. L. Tumor-derived exosomes and their role in cancer progression. Signal Transduct Target Ther 9, 138 (2024).

Li, Z., Wang, X., Wang, X. et al. Research progress on the role of extracellular vesicles in neurodegenerative diseases. Transl Neurodegener 12, 43 (2023).

Extracellular vesicles in cancer — implications for future diagnostics and therapeutics. Nature Reviews Clinical Oncology 15, 83 (2018).

Kalluri, R., McAndrews, K.M. The role of extracellular vesicles in cancer. ScienceDirect 13, 263 (2023).

Herrmann, I.K., Wood, M.J.A., Fuhrmann, G. Extracellular vesicles as a next-generation drug delivery platform. Nat. Nanotechnol. 16, 748–759 (2021).

Extracellular vesicles and neurodegenerative diseases. Journal of Neuroscience 39, 9269 (2019).

Raghav, A., Singh, M., Jeong, G.-B. et al. Extracellular vesicles in neurodegenerative diseases: A systematic review. Int. J. Mol. Sci. 22, 138 (2022).

Majood, M., Rawat, S., Mohanty, S. Delineating the role of extracellular vesicles in cancer metastasis: A comprehensive review. Front. Immunol. 13, 966661 (2022).

Kalluri, R. The biology and function of exosomes in cancer. JCI 15, 83 (2016).

Wang, X., et al. Exosomes and Their Role in Cancer Progression. Front. Oncol. 11, 639159 (2021).

 

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1.  Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217
2. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. bioRxiv 2025.04.15.648836v1 https://www.biorxiv.org/content/10.1101/2025.04.15.648836v1
3.  American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity  Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.

 

 

Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories

 

Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)